In This Article:
TG Therapeutics reported a 3.7% increase in its stock price over the last week, coinciding with the company's announcement of strong fourth-quarter earnings results and optimistic earnings guidance for 2025. The company revealed a significant jump in revenue to $108 million and a transition to profitability, posting a net income of $23 million for Q4 2024. The positive outlook, particularly for its BRIUMVI product, was emphasized in their earnings guidance, projecting approximately $540 million in global revenue for 2025. These developments stood out against a broader market backdrop where major U.S. indices experienced declines, with the Nasdaq falling 1.4% during the same period. Despite ongoing economic uncertainty affecting the market, TG Therapeutics' strong financial performance and optimistic future projections appear to have supported its recent stock price appreciation.
Unlock comprehensive insights into our analysis of TG Therapeutics stock here.
Over the past three years, TG Therapeutics' shares have delivered a substantial total return of 247.06%, driven by several key developments. The company was added to major indices, including the S&P 600 and S&P Composite 1500 in September 2024, boosting investor visibility and confidence. Additionally, the company announced an agreement with Neuraxpharm Group in August 2023 to expand BRIUMVI's commercialization outside the U.S., signaling international growth opportunities.
In November 2024, TG Therapeutics completed a share buyback program, enhancing shareholder value. Clinical advancements were highlighted by FDA clearance in August 2024 for a new multiple sclerosis treatment, azer-cel, further broadening the company's pipeline. The company's performance exceeded the U.S. market, which returned 15.3% over the past year, and outperformed the biotech industry, which experienced a 6.9% decline, underscoring its strong relative performance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.